Trastuzumab biosimilar PBS-listed

Among its indications are for patients with HER2-positive advanced adenocarcinoma of the stomach
Clare Pain
woman in pink top wearing pink ribbon to denote breast cancer

A biosimilar of trastusumab, Ogivri (Mylan), was listed on the PBS on 1 August.

The biosimilar is available as a 150mg injection and is indicated for HER2-positive early breast cancer in combination with chemotherapy, and possibly also radiotherapy.